Related Experiment Video
Updated: Apr 17, 2026
07:22
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024
4.9K
Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications.
Nikola Knoll1, Nouri Neamati2, Aykut Üren1
1Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20007, United States.
ACS Pharmacology & Translational Science
|April 16, 2026
Summary
Proteolysis-targeting chimeras (PROTACs) harness the ubiquitin-proteasome system to degrade disease-causing proteins. This innovative technology offers a new therapeutic approach, expanding treatment options for various diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- The ubiquitin-proteasome system (UPS) is crucial for protein homeostasis, degrading unwanted proteins.
- Targeted protein degradation utilizes the UPS to eliminate specific proteins of interest (POIs).
Purpose of the Study:
- This review details the design principles of proteolysis-targeting chimeras (PROTACs).
- It discusses the advantages and limitations of PROTACs as research tools and therapeutics.
Main Methods:
- PROTACs are bifunctional molecules that recruit E3 ligases to POIs, marking them for proteasomal degradation.
- The review synthesizes current knowledge on PROTAC design and application.
Main Results:
- PROTACs have revolutionized drug discovery, expanding the range of druggable targets.
- Over 30 PROTACs are in clinical trials, with early successes against disease drivers.
- PROTACs enable targeting previously "undruggable" proteins like transcription factors.
Conclusions:
- PROTAC technology has significant potential as a key therapeutic modality.
- PROTACs may greatly improve patient survival and quality of life for various diseases.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
5.1K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
5.1K
01:17The Proteasome Structure
2.3K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
2.3K
02:53Conservative Site-specific Recombination and Phase Variation
7.4K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
7.4K